Hypogonadism and prostate cancer detection on multiparametric MRI and mpMRI-TRUS fusion biopsy.
Dordaneh SuganoAbhinav SidanaAmit L JainBrian CalioSonia GaurMahir MarufMaria MerinoPeter ChoykeBaris TurkbeyBradford J WoodPeter A PintoPublished in: International urology and nephrology (2019)
Hypogonadism is an independent predictor of lower CS cancer detection on systematic biopsy. However, it fails to significantly impact CS detection on fusion biopsy with comparable cancer detection rates in both groups. Patients with hypogonadism may benefit more from fusion biopsy than normogonadal patients.
Keyphrases
- prostate cancer
- loop mediated isothermal amplification
- ultrasound guided
- fine needle aspiration
- label free
- real time pcr
- papillary thyroid
- replacement therapy
- magnetic resonance imaging
- newly diagnosed
- end stage renal disease
- radical prostatectomy
- squamous cell carcinoma
- computed tomography
- contrast enhanced
- smoking cessation
- childhood cancer